Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Head and Neck Cancer
Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898430
- Testing
- DNA Microarray analysis, MALDI-TOF mass spectrometry, DNA microarray and MALDI-TOF mass spectrometry
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Squamous Cell Carcinoma (ESCC)
BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)
This is an open-label, single arm, multi-center study, assessing efficacy and safety of BI-754091 in combination with afatinib as treatment in patients with advanced or metastatic ESCC refractory to at least 1 line of systemic…
- Trial name
- BEAR (NCT04839471)
- Testing
- BI-754091 plus afatinib
- Where
- 4 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- National Health Research Institutes, Taiwan
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally…
- Trial name
- MERIDIAN (NCT05414032)
- Testing
- AZD2936
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- University Health Network, Toronto
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004901
- Testing
- ethynyluracil, fluorouracil, hydroxyurea
- Where
- 2 sites in United States
- Sponsor
- Robert H. Lurie Cancer Center
the Records of Esophageal Cancer
RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY
To clarify the effect of the number of lymph node dissection and the number of stations on survival
- Trial name
- NCT05570487
- Testing
- Since the data were collected retrospectively, there were no interventions
- Where
- China
- Volunteers
- 1,600 people
- Sponsor
- Yongtao Han
Squamous Cell Carcinoma Mouth
Primary Tumor Depth of Invasion and Lymph Node Management in Oral Squamous Cell Carcinoma
To evaluate the diagnostic accuracy of preoperative MRI in the determination of the primary tumor depth of invasion (DOI) as a predictor factor in neck lymph nodes management in T1T2N0 oral cavity squamous cell carcinomas as…
- Trial name
- NCT07127614
- Testing
- MRI, Histo-Pathological examination of the resected tumor tissues
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Al-Azhar University
Head and Neck Squamous Cell Carcinoma
Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck Cancer
The purpose of this study is to evaluate the use of Transoral Robotic Surgery (TORS) to identify small oropharyngeal carcinomas.
- Trial name
- FIND (NCT03281499)
- Testing
- da Vinci Surgical System Model IS4000
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto
Hypopharyngeal Carcinoma, Immunotherapy
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
This is a single-center, multidisciplinary, open-label, single-arm prospective clinical study.
- Conditions
- Hypopharyngeal Carcinoma, Immunotherapy, Chemotherapy
- Trial name
- NCT04156698
- Testing
- Docetaxel, Cisplatin, Capecitabine
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Esophageal Cancer, Sentinel Lymph Node
A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
In the comprehensive treatment system for esophageal cancer, surgical resection combined with regional lymph node dissection remains the core component for achieving cure in patients with resectable esophageal squamous cell…
- Conditions
- Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy, Indocyanine Green (ICG)
- Trial name
- SIGN (NCT07788001)
- Testing
- ICG-guided sentinel lymph node dissection, ICG-guided systematic lymph node dissection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fujian Medical University Union Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with…
- Trial name
- NCT05342636
- Testing
- Pembrolizumab, Coformulation favezelimab/pembrolizumab, MK-4830
- Where
- 46 sites in Brazil, Chile and 11 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Mouth Neoplasms, Oropharyngeal Neoplasms
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
This is an imaging protocol only, not a therapeutic study. The primary goal of the proposed study is to examine the utility of a new imaging study, Positron Emission Tomography with F-18 Fluorothymidine (FLT PET), in the early…
- Conditions
- Mouth Neoplasms, Oropharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT00721799
- Testing
- 18F-Fluorothymidine PET scan
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Iowa
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It may also stop the growth of tumor cells by stopping blood flow to the tumor.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00096512
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of neoadjuvant PD-1 blockade monotherapy with toripalimab in elderly patients with locally advanced resectable esophageal squamous…
- Trial name
- BLESS (NCT06385730)
- Testing
- neoadjuvant anti-PD-1, neoadjuvant anti-PD-1 with LDRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Chest Hospital
Head and Neck Squamous Cell Carcinoma
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
The primary objective of this clinical study is to compare the pharmacokinetic parameters of drugs RPH-002 and Erbitux® after a single intravenous administration, as well as to evaluate the safety of drug RPH-002 in comparison…
- Trial name
- NCT07435311
- Testing
- RPH-002, Erbitux®, cisplatin
- Where
- 18 sites in Russia
- Volunteers
- 118 people
- Sponsor
- R-Pharm
Advanced Solid Tumor
Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors
This study is a Phase I/IIa, multi-center, open-label study of BR790 in combination with Tislelizumab with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors.
- Trial name
- NCT05505877
- Testing
- BR790+Tislelizumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Gopherwood Biotech Co., Ltd.
Head and Neck Cancer, Head and Neck (HNSCC)
APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma
This Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
- Conditions
- Head and Neck Cancer, Head and Neck (HNSCC), Oropharyngeal, Oral Cavity
- Trial name
- NCT07667296
- Testing
- APG-157, Surgery, Radiation/Chemotherapy
- Volunteers
- 826 people
- Sponsor
- Aveta Biomics, Inc.
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous cell carcinoma (CSCC) respond to…
- Trial name
- NCT04242173
- Testing
- Cemiplimab-Rwlc
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Squamous Cell Carcinoma of the Head and Neck
Functional ImaGing of Heterogeneity in Head and Neck Tumors - Validation From Surgical Specimens
The purpose of this study is to investigate if heterogeneity in head and neck squamous cell carcinoma as seen in functional imaging with PET/MR can be correlated to biologic heterogeneity in surgical specimens.
- Trial name
- FIGHHT (NCT03160495)
- Testing
- All patients
- Where
- Denmark
- Volunteers
- 33 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Esophageal Squamous Cell Carcinoma
Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
This study is a prospective, open-label, single-arm, single-center clinical study, aiming to evaluate the efficacy and safety of sintilimab combined with platinum-based chemotherapy + pegylated recombinant human granulocyte…
- Trial name
- NCT06563869
- Testing
- PEG-rhG-GSF
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.